BioViva, a trail-blazing medical data analysis and research and development company, was started to change the face of healthcare treatments by bringing enhanced and definitive solutions for some of the most perilous diseases. The inspiration came from a life-changing incident when the founder’s son was diagnosed with Type 1 Diabetes. On the path to find the most adequate treatment for him, she was confronted with the reality of children suffering from genetic diseases. She also discovered that, although laboratory animals have been successfully treated for many of these diseases, those therapies haven’t yet been made available to humans, because of the medical profession’s exaggerated risk aversion and the FDA’s precautionary attitude. This meant that despite the discovery of appropriate therapies, the kids die because these therapies have not yet been through a lengthy and extremely expensive chain of paperwork and clinical trials. Determined to change this condition, she established BioViva.
Today, BioViva analyzes biomarkers from trials and studies involving patients referred to the clinics by its partner company, Integrated Health Systems. The company is focused on speeding up the number of medical innovations by cooperating with companies that offer consenting patients pioneering therapies that they cannot get in the United States. Using medical researchers to oversee the patients, it beats the gold standard of the US FDA and creates exponential technology for the future. BioViva is the first company in the world to look at the data of regenerative gene therapies in humans.
The Multi-faceted Kingpin
Elizabeth Parrish, the Founder and CEO of BioViva, is a humanitarian, entrepreneur, innovator, author, podcaster, and a leading voice for genetic cures. As a strong proponent of progress and education for the advancement of regenerative medicine modalities, she serves as a motivational speaker to the public at large for the life sciences. She is actively involved in international educational media outreach. Dedicated to the cause of improving and safeguarding more and more lives, Elizabeth asserts, “We are focused on saving as many lives as possible by making tomorrow’s therapies available. This is about Life and Death. Risk aversion and the delaying the approval of therapies that have been successful in research simply kills.”
BioViva provides gene testing kits that allow customers to learn information about their own genome from various perspectives, such as their biological age, risk for various diseases, etc. It is the only company in the world that has access to data from patients who are taking regenerative gene therapies. Additionally, the company is launching a multi-omics repository for clients to upload their data, regardless of what company they obtained it from, allowing the customer to have all their health data in one place. BioViva works in partnership with Integrated Health Systems to help people access advanced therapeutics. Concentrating on research and development, it is designing a new gene therapy delivery method to solve the very important problem of cell delivery of genes.
The company also has an explicit focus on aging as a disease, because, according to BioViva, aging is a disease that underlies many others. “Time is your most valuable asset, we want you to have more of it. Creating a world with longer healthier lifespans gives us time to solve climate change and to come together as a species to solve social impact and reduce racism,” says Elizabeth.
Shrewd Insight on Gene Therapy
BioViva believes that gene therapy offers a permanent cure for a variety of diseases; it is the answer to monogenic diseases, such as progeria, and cystic fibrosis, as well to hemophilia b and sickle cell anemia. However according to the experts at BioViva, it also offers promise in the case of more complex diseases involving multiple genes. Addressing the same, Elizabeth says, “I regard aging as the master disease in this respect. By changing a set of genes such as the gene coding for the enzyme telomerase or the protein inhibitor follistatin, you can alter a person’s biological age, and thereby make him or her healthier, because youth is health, and old age is sickness. Aging is cellular degeneration over time, with gene therapy we can make the cell regenerate faster than it degenerates. I therefore regard gene therapy as the future, because it will address the scourge of aging with increased success, and we are working to offer first generation therapies to people who need them now.”
Into a Bright Future
BioViva has currently funded the Rutger’s University to work on developing a better vector for future gene therapy than the existing solution. It foresees that this project will be almost ready for future use in next five years. Additionally, the company hopes to have amassed the data that shows how different gene therapies, at least ten of them by 2024, have worked in humans, in the next five years.